期刊文献+

增生性瘢痕防治研究进展与挑战 被引量:4

原文传递
导出
摘要 增生性瘢痕(hypertrophic scar,HS)是烧(创)伤后组织过度修复的结果,严重影响患者的生存质量,其防治一直是临床及基础研究的焦点问题。本文围绕HS的发生机制、实验模型进行阐述,并就现存问题与发展趋势提出自己的观点。
作者 贾赤宇
机构地区 解放军第三
出处 《中华烧伤杂志》 CAS CSCD 北大核心 2012年第5期393-395,共3页 Chinese Journal of Burns
基金 国家重点基础研究发展计划(2012CB518104) 全军医学科学技术研究“十二五”计划专项课题(BWS11C061) 北京市自然科学基金(7122179、7123229)
  • 相关文献

参考文献24

  • 1Grieb G, Steffens G, Pallua N, et al. Circulating fibrocytes-bi-ology and mechanisms in wound healing and scar formation. Int Rev Cell Mol Biol, 2011,291:1-19.
  • 2Ali SS, Hajrah NH, Ayuob NN, et al. Morphological and mor- phometric study of cultured fibroblast from treated and untreated abnormal scar. Saudi Med J, 2010,31 (8) :874-881.
  • 3李明勇,邱林.转化生长因子β3与创面愈合及瘢痕形成关系研究进展[J].中华烧伤杂志,2010,26(1):59-61. 被引量:6
  • 4Abdou AG, Maraee AH, A1-Bara AM, et al. Immunohistochemi- cal expression of TGF-β1 in keloids and hypertrophic scars. Am J Dermatopathol, 2011,33(1 ) :84-91.
  • 5李喆,李世荣,刘剑毅,戴霞,陶灵.结缔组织生长因子介导转化生长因子β1促进瘢痕成纤维细胞转分化的研究[J].中华烧伤杂志,2009,25(1):49-52. 被引量:8
  • 6王西樵,刘英开,青春,陆树良.增生性瘢痕演变过程中内皮细胞生物学功能变化[J].中华烧伤杂志,2010,26(4):276-278. 被引量:3
  • 7Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scar- ring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011,17(1/2) :113-125.
  • 8Berman B. Biological agents for controlling excessive scarring. Am J Clin Dermatol, 2010,11 Suppl 1:31-34.
  • 9van der Veer WM, Ferreira JA, de Jong EH, et al. Perioperative conditions affect long-term hypertrophic scar formation. Ann Plast Surg, 2010,65 (3) :321-325.
  • 10Yang JY, Huang CY. The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: a new strategy for the treatment of hypertrophic scars. Dermatol Surg, 2010,36(12) :1942-1949.

二级参考文献83

共引文献19

同被引文献37

  • 1叶小珍,邵加庆,王坚.花生四烯酸及其代谢产物在胰岛β细胞功能及胰岛素抵抗中的作用[J].中国全科医学,2009,12(2):160-162. 被引量:3
  • 2罗佳,章敬成,刘繁荣,吴冬梅,廖首生,杨宇晴.肝癌组织中FMNL-2和MMP-2的表达及临床病理分析[J].肿瘤防治研究,2014,41(5):460-463. 被引量:6
  • 3温学辉,付小兵,孙同柱,郭振荣.保留不同厚度脂肪组织对猪烧伤创面收缩的影响[J].感染.炎症.修复,2007,8(1):14-18. 被引量:16
  • 4Mair M, Blaas L, Osterreicher CH, et al. JAK-STAT signaling in he-parle fibrosis[J]. Front Biosci(Landmark Ed), 2011 ,(16) :2794-2811.
  • 5Vera J, Rateitschak K, Lange F, et al. Systems biology of JAK- STAT signaling in human malignancies[J]. Prog Biophys Mol Bi- ol, 2011,106(2) :426-434.
  • 6Matsui F, Meldrum KK. The role of the Janus kinase family/signal transducer and activator of transcription signaling pathway in fibrot- ic renal disease[ J ]. J Surg Res, 2012,178 (1) :339-345.
  • 7Jatiani SS, Baker SJ, Silverman LR, et al. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies [ J ]. Genes Cancer, 2010,1 ( 10 ) :979-993.
  • 8Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis[ J]. J Immunol, 2005,175 (9) :617745189.
  • 9Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacety- lase activity attenuates renal fibroblast activation and interstitial fi- brosis in obstructive nephropathy[J]. Am J Physiol Renal Physiol, 2009,297(4) : 1;996-F1005.
  • 10Martfnez-Caselles A, Pons-Minano JA, Vargas-Acosta A, et al. Hepatoportal sclerosis clinical different evolutionary stages: pres- entation of 3 cases and literature review [ J ]. Rev Esp Enferm Dig, 2012,104(2) :94-97.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部